Cancer Vaccine in the US Is Booming
A new research report entitled "US Cancer Vaccine Market Outlook 2020", by RNCOS reveals that 21 promising studies in phase-3 clinical trials are expected to yield possible therapeutic cancer vaccine products in the very near future. Currently, more than 20% of the therapeutic cancer vaccines in phase-3 clinical trials are for the treatment of lung cancer. This is reflective of the high demand that exists owing to the high incidence and prevalence of lung cancer in US. But for other...
View full press release